pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Exdensur
drug
save

depemokimab

Marketedupdated 6mo ago
by $GSK GSK plc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugEXDENSUR4 co-mentions · 1 sources
  • tagApproval4 co-mentions · 1 sources
  • companyGlaxoSmithKline LLC2 co-mentions · 1 sources

indications

investigational
Asthma

all catalysts(1)

approval · 1
Dec 16, 2025
approval
11mo ago
EXDENSUR (DEPEMOKIMAB-ULAA) — FDA approval
depemokimab
→

Trials studying depemokimab

  • phase3Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trialrecruitingn=109
  • phase3A Study of Depemokimab in Participants of 6 to 11 Years of Agerecruitingn=34
  • phase4Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)not yet recruitingn=28
  • phase3Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)active not recruitingn=163
  • phase3Depemokimab Asthma Imaging and Bronchoscopy Sub-Studyrecruitingn=150
  • phase3Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)recruitingn=960
  • phase3A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthmanot yet recruitingn=456
  • phase3An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)completedn=641

News(2)

  • Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
    Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
    biopharma_dive · 21d ago
  • GSK vaccine sales miss expectations amid falling demand from adults
    With pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.
    biospace · 23d ago
brand
Exdensur
generic
depemokimab-ulaa
indication
Nasal Polyps (Nasal Polyposis)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?